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Introduction
Precision oncology relies on treating individual tumors with drugs 
that target their specific vulnerabilities. Cancer cells are often 
characterized by the constitutive activation of an oncogenic sig-
naling cascade to which they become dependent (oncogene addic-
tion), a liability that can be exploited for therapy (1). For example, 
half of all melanomas are characterized by oncogenic BRAF muta-
tions, which render them susceptible to treatment with BRAF 
inhibitors. Yet, subsets of tumor cells may carry intrinsic (primary) 
resistance or initially drug-sensitive cells may subsequently devel-
op refractoriness to oncogene inhibitors (acquired resistance), 
thereby nullifying the efficacy of targeted therapy (2–4). Thus, 
major challenges are the identification of tumor traits that pre-
dict drug susceptibility and the development of novel therapeutic 
approaches to prevent or delay the onset of drug resistance by dis-
abling underlying molecular mechanisms. Concomitant genetic 
changes found in tumors may be responsible for primary refrac-
toriness to targeted therapies or — when present at the subclonal 
level — may lead to outgrowth of drug-resistant tumors over time. 
However, targeted therapies often cease to be effective due to 
adaptive mechanisms triggered in response to treatment (5). For 
instance, resistance to oncogene-targeted drugs is frequently due 
to the upregulation of parallel signaling cascades, which can sus-
tain cancer cell viability and proliferation despite the blunting of 
the pathway to which the tumor is addicted. In particular, it has 
been shown that cancer cells can exploit the presence of cytokines 
and growth factors in the tumor microenvironment by increasing 
the expression and/or activity of tyrosine kinase receptors, such as 
EGFR, HGFR, FGFR, and others (6). Although these changes may 
be reversible in principle, they nonetheless jeopardize the clinical 
efficacy of targeted inhibitors, leading to progressive disease.
Neuropilin-1 (NRP1) is a transmembrane protein overex-
pressed in advanced human tumors, typically showing growth- 
promoting functions in cancer cells (7, 8). NRP1 was initially 
described as a coreceptor for secreted semaphorins and for vascu-
lar endothelial growth factors (VEGFs), in association with plexins 
or VEGF receptors, respectively. However, we have shown that 
NRP1 also interacts with epidermal growth factor receptor (EGFR) 
at the cell surface, promoting ligand-induced EGFR clustering 
and intracellular signaling (9). Additional growth factor–induced 
signaling cascades have been associated with NRP1, though the 
implicated molecular mechanisms remain largely unclear (10). 
Thus, NRP1 seems to act as a receptor hub on the cell surface, pro-
moting multiple signaling cascades (11, 12).
The mechanisms modulating NRP1 expression in cancer cells 
are still controversial. For instance, NRP1 may be transcriptionally 
induced by growth factors and by the activation of the RAS-MAPK 
signaling pathway (13–15); on the other hand, NRP1 transcripts are 
proposed targets of miRNA-338 (16) and other miRNAs. Notably, 
NRP1 is widely expressed in carcinoma cells (although at differ-
ent levels), whereas it is hardly present in neural crest derivatives, 
including melanocytes and melanoma cells.
Previous studies support the notion that elevated NRP1 expres-
sion in tumors correlates with poor outcome (7, 12); however, the 
underlying mechanisms have not been elucidated. In the present 
study, we explore the hypothesis that NRP1 expression confers 
a growth advantage to oncogene-addicted cancer cells treated 
with targeted inhibitors, thus contributing to drug resistance. We 
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NRP1 and EGFR (Figure 1B). On the other hand, SOX10 was 
downregulated in 80% of the treated tumors, in keeping with its 
posited role in regulating both NRP1 and EGFR (Figure 1B).
In order to investigate the relevance of NRP1-dependent sig-
naling in the onset of BRAF-inhibitor resistance, we established 
stable drug-resistant A375 and SK-MEL-28 melanoma cells by pro-
longed treatment in culture with escalating doses of PLX-4720 (an 
analogue of the clinically approved BRAF-targeted agent vemu-
rafenib), until the surviving cells refractory to therapy displayed 
comparable viability to untreated parental cells (Supplemental 
Figure 1E). In multiple independent batches of drug-resistant cells, 
SOX10 mRNA levels were consistently decreased, whereas both 
NRP1 and EGFR were strongly upregulated at mRNA and protein 
levels (Figure 1, C and D and Supplemental Figure 1F). Notably, 
drug-resistant cell viability relied on both NRP1 and EGFR expres-
sion, whereas parental cells were not dependent on these genes 
(Figure 1E and Supplemental Figure 1G), suggesting the acquisition 
of a novel addiction pathway in melanoma cells becoming resistant 
to BRAF inhibitors. In order to establish the upstream mechanism 
driving resistance, we assayed the effect of NRP1 knockdown prior 
to therapy and found that this was sufficient to prevent the adap-
tive EGFR upregulation induced by BRAF-inhibitor treatment (Fig-
ure 1F). In fact, NRP1 expression was required to maintain EGFR 
induction in SOX10-depleted and stably drug-resistant melano-
ma cells (Supplemental Figure 2, A and B). In a complementary 
approach, restoring EGFR overexpression (by cDNA transfer) in 
formerly drug-resistant melanoma cells subjected to NRP1 silenc-
ing was sufficient to rescue cell viability and growth in the presence 
of the BRAF inhibitor (Supplemental Figure 2, C and D); hence, 
EGFR qualifies as a major player of drug resistance downstream 
to NRP1. The specific functional role of NRP1 in the onset of drug 
resistance was also indicated by the fact that NRP1 knockdown did 
not impact the A375 cell growth rate under basal conditions (i.e., in 
the absence of the drug). However, after 5 weeks of culture in the 
presence of PLX-4720, NRP1-depleted melanoma cells were still 
significantly sensitive to therapy and their growth was strikingly 
slowed (Figure 1, G and H, and Supplemental Figure 2E), whereas 
control cells had developed full adaptive resistance. The relevance 
of NRP1 in drug resistance was ultimately demonstrated in vivo 
by treating mice bearing tumor xenografts of drug-resistant A375 
melanoma cells, subjected to NRP1 silencing, with PLX-4720 (Fig-
ure 1I). Consistent with findings in culture, NRP1 knockdown did 
not impact tumor growth in vivo in the absence of the drug; how-
ever, it could successfully restore sensitivity to targeted therapy 
in this preclinical model of drug-resistant melanoma xenografts 
(Figure 1I). Altogether, these data indicate that NRP1 is induced in 
response to BRAF inhibitors and is a pivotal driver of resistance to 
BRAF-targeted therapy in melanoma. Intriguingly, we found that 
the NRP1 ligand VEGF was two-thirds fold induced in our drug- 
resistant melanoma cells (not shown). Since VEGF-NRP1 signaling 
has been previously found to promote cancer cell growth and sur-
vival (18–22), we hypothesized that VEGF could be the trigger of 
this novel drug-resistance pathway; however, this doesn’t seem to 
be the case, as there was no change in melanoma cell drug respon-
siveness upon VEGF silencing (Supplemental Figure 2, F and G).
We also studied the mechanism underlying the observed 
NRP1 transcriptional upregulation in drug-resistant SOX10- 
investigated melanoma cells characterized by BRAF-activating 
mutations and oncogenic addiction, as well as several carcinoma 
lines derived from stomach, lung, or breast cancer carrying MET 
or HER2 oncogene amplification and constitutive signaling. Our 
data reveal a novel role for NRP1 in controlling the therapeutic 
response to targeted oncogene inhibitors, and identify NRP1 as a 
novel target for therapy to fight drug resistance.
Results
BRAF-inhibitor resistance in melanoma cells is dependent on NRP1 
de novo expression, associated with the downregulation of the SOX10- 
effector miRNA-338. As a prototypical example of oncogenic addic-
tion, approximately half of melanomas carry a constitutively acti-
vated BRAF kinase, whereby the treatment with targeted inhibitors 
initially achieves remarkable therapeutic success. Unfortunately, 
drug resistance often ensues, dependent on the upregulation of 
alternative signaling pathways (3). For instance, we have previ-
ously shown that BRAF-addicted melanoma cells, upon treatment 
with targeted inhibitors, undergo adaptive gene expression repro-
gramming and develop drug resistance associated with the down-
regulation of the transcription factor SOX10 (17), a known marker 
of neural crest lineage differentiation. This was associated with 
the upregulation of the EGFR tyrosine kinase, as well as of other 
growth factor receptor signaling cascades such as TGFBR2 and 
PDGFRB. Yet, the pathway responsible for these adaptive chang-
es has not been fully elucidated. Intriguingly, we and others have 
demonstrated a role for NRP1 in controlling cancer cell growth 
by promoting signaling cascades mediated by EGFR, TGFβR, 
PDGFR, and others (11). In fact, melanoma cells typically car-
ry barely detectable NRP1 (see Supplemental Figure 1A; supple-
mental material available online with this article; https://doi.
org/10.1172/JCI99257DS1), implying that it is not basally required 
for their viability. However, in a genome-wide expression analysis 
previously performed (17), NRP1 was the third most upregulated 
gene in SOX10-deficient cells refractory to BRAF inhibitors, sug-
gesting a role for NRP1 in adaptive drug resistance. We initially val-
idated this unbiased finding by quantitative PCR (qPCR) analysis, 
confirming NRP1 upregulation in a range of melanoma cell lines 
in which SOX10 was selectively silenced by means of 2 indepen-
dent shRNAs (Figure 1A and Supplemental Figure 1B). As expect-
ed, EGFR transcripts were also increased in SOX10-silenced cells 
(Figure 1A and Supplemental Figure 1B). The effect was reproduc-
ible both in BRAF-mutated (A375, SK-MEL-28, and SK-MEL-5) 
and BRAF-WT melanoma cells (SK-MEL-2), indicating that it is 
independent of BRAF oncogenic mutations and underscoring the 
upstream regulatory function of the SOX10 transcription factor. 
Expression analysis of 472 melanoma samples from The Cancer 
Genome Atlas (TCGA) database indicated an inverse correlation 
between SOX10 and NRP1 levels (Spearman’s correlation coeffi-
cient: –0.542; P < 0.00001; Supplemental Figure 1C). Moreover, 
there was a direct association between NRP1 and EGFR expression 
in the same samples (Spearman’s correlation coefficient: 0.432; 
P < 0.00001; Supplemental Figure 1D). We corroborated these in 
silico analyses by assessing NRP1, EGFR, and SOX10 expression 
in a panel of matched melanoma samples derived from the same 
patients before and after treatment with BRAF inhibitors. Indeed, 
we found substantial evidence of concomitant upregulation of 
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Figure 1. Adaptive NRP1 neoexpression in BRAF-addicted melanoma cells mediates acquired resistance to targeted therapy. (A) Different melano-
ma cells were subjected to SOX10 knockdown (KD) by inducible shRNA expression, and SOX10, NRP1, and EGFR mRNA levels were analyzed by qPCR 
(n = 4). The graph shows log2 fold change variations in SOX10-KD cells versus respective controls. (B) Box plot showing SOX10, NRP1, and EGFR mRNA 
expression variations in 12 paired melanoma samples (indicated by different symbols) obtained from the same patients before and during treatment 
with BRAF inhibitors (log2 ratio treated/untreated). (C) qPCR analysis of SOX10, NRP1, and EGFR expression in A375 and SK-MEL-28 melanoma cells that 
developed acquired resistance to 2 μM PLX-4720 (log2 ratio drug resistant versus parental cells; n = 3). (D) SOX10, NRP1, and EGFR protein expression in 
the same cells shown in C; vinculin and β-tubulin levels provided loading controls (1 representative experiment of 3 repetitions; duplicate samples were 
run on parallel gels for staining with different antibodies). (E) The viability of parental or drug-resistant A375 cells was assessed upon NRP1 or EGFR KD 
with targeted siRNAs (n = 5). (F) A375 parental cells were subjected to NRP1 KD (by targeted shRNAs) before exposure to escalating concentrations of 
PLX-4720 aimed at establishing drug resistance. NRP1 and EGFR expression was analyzed after 5 weeks of treatment. The statistical analysis compared 
NRP1-KD samples with respective controls (carrying plkO empty vector) (n = 3). (G) The growth rate of control or NRP1-KD A375, either untreated or 
exposed to 0.5 μM PLX-4720 for 5 weeks, is scored as the percentage of increase of viable cells across 72 hours (n > 3). (H) The growth rate of control or 
NRP1-KD A375 cells on therapy with 0.5 μM PLX-4720 for 5 weeks was tracked in culture over 7 days (n > 3). (I) Mice implanted with either mock- 
transduced or NRP1-KD drug-resistant A375 cells were treated daily with 20 mg/kg PLX-4720 (or vehicle only), and the tumor burden was periodically 
measured. The statistical analysis compared treated tumors with respective controls (n = 5, per condition). For E, F, G, statistical significance was deter-
mined using a Student’s t test with Bonferroni’s correction (*P < 0.01; **P < 0.001; ***P < 0.0001); for H and I, a 2-way ANOVA test with Bonferroni’s 
correction was used (***P < 0.0001).
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derived from gastric cancer, 
and EBC1 and H1993 derived 
from lung cancer. As previously 
reported, these cells are crucial-
ly dependent on MET tyrosine 
kinase activity and their viabili-
ty is severely impaired by treat-
ment with the MET-specific 
kinase inhibitors JnJ-38877605 
(JNJ-605) or PHA-665752, or 
the clinically approved multi-
kinase inhibitor crizotinib 
(25). These cells constitutively 
express NRP1 (Figure 3A), but 
its knockdown by shRNAs (val-
idated in Supplemental Figure 
3A) did not affect their viability 
or proliferation rate (Figure 3B 
and Supplemental Figure 3B), 
indicating that these oncogene- 
addicted cells are not dependent 
on NRP1 expression. Nonethe-
less, NRP1-depleted cells dis-
played significantly increased 
sensitivity to anti-Met agents 
(IC50 was reduced by half, or 
more), as shown by the impaired 
cell viability and growth in the 
presence of MET inhibitors both 
in short-term (Figure 3, C–H) and 
long-term experiments (Figure 3, 
I and J). Altogether, our data in BRAF and MET oncogene–addicted 
cells suggest that NRP1 expression becomes crucial when the driver 
pathway sustaining proliferation is blocked by targeted inhibitors.
In a complementary approach, since adaptive (de novo) NRP1 
expression in melanoma cells is required to drive resistance to 
BRAF inhibitors, we asked whether enhanced NRP1 expression 
in MET-addicted cancer cells could impair sensitivity to targeted 
therapy. Indeed, stably NRP1-overexpressing cells demonstrat-
ed relative refractoriness (or overt primary resistance) to target-
ed inhibitors, with remarkably increased IC50 values compared 
with controls (Figure 4, A and B). Consistent with the findings in 
drug-resistant melanoma cells, these data suggest that increased 
NRP1 levels confer a selective advantage to MET-addicted cancer 
cells subjected to targeted therapy. In order to test this hypothesis 
in vivo, we established heterogeneous tumor xenografts in mice 
by injecting a mix of both MET-addicted carcinoma cells over-
expressing NRP1 and those mock transduced. Notably, in each 
experimental group, 1 of the 2 cell populations had been fluores-
cently labeled to score its representation in the growing tumors. 
In the absence of any selective therapeutic pressure, both cancer 
cell populations showed similar growth rates in vivo (Figure 4C, 
solid lines). In contrast, upon treatment with a MET inhibitor (dot-
ted lines), control cells were selectively curbed (further validated 
in Supplemental Figure 4, A and B), enabling the overgrowth of 
NRP1-overexpressing cells within the heterogeneous tumors (Fig-
ure 4C). Indeed, based on the fluorescent signal (Figure 4C) and 
depleted melanoma cells. Interestingly, SOX10, in addition to 
positively controlling the promoter of neural crest lineage differ-
entiation genes, is also known to induce the expression of several 
micro-RNAs, including miR-338-3p (23), which was reported to 
downregulate NRP1 expression in cancer cells (16, 24). We ver-
ified, in a transcriptome data set of 57 different melanoma cell 
lines, that the expression of SOX10 and miR-338 are strongly cor-
related (Spearman’s correlation coefficient: 0.539; P = 2.9 × 10–5), 
whereas in contrast they are both inversely correlated with NRP1 
(Supplemental Figure 2H). Importantly, miR-338 levels were 
strikingly decreased in SOX10lo/NRP1hi drug-resistant A375 and 
SK-MEL-28 melanoma cells (Figure 2A). Conversely, miR-338 
reexpression in resistant cells strongly reduced NRP1 and EGFR 
mRNA and protein levels (Figure 2, B and C). Moreover, drug sen-
sitivity was restored in resistant cells upon miR-338 forced reex-
pression (Figure 2D). These data identify a SOX10-miR338-NRP1 
regulatory axis, which could account for the low levels of NRP1 
in neural crest–derived cells, including melanocytes and mela-
noma cells. Moreover, this could explain the increase in NRP1 
expression (upon SOX10 and miR-338 downregulation) in BRAF 
inhibitor–resistant cells.
NRP1 controls response to targeted therapy in MET oncogene–
addicted cancer cells. In order to generalize the above findings and 
extend the relevance of NRP1 to cancer cells addicted to differ-
ent oncogenes, we analyzed 3 carcinoma cell lines carrying MET 
oncogene amplification and constitutive signaling: namely, GTL16 
Figure 2. miRNA-338 downregulation mediates NRP1 neoexpression in BRAF inhibitor–resistant melanoma 
cells. (A) The expression of miRNA-338-3p was assessed by quantitative real-time PCR in PLX-4720–resistant 
A375 and SK-MEL-28 melanoma cells, and normalized versus the respective parental cells (n = 5). Student’s t test, 
***P < 0.0001. (B) qPCR analysis of NRP1 (left graph) and EGFR (right graph) expression in drug-resistant A375 
and SK-MEL-28 cells, transfected in order to reexpress miR-338 (values normalized to respective mock-transfect-
ed cells) (n = 4). (C) NRP1 expression assessed by immunoblotting in parental and PLX-4720–resistant A375 cells 
transfected with pre–miRNA-338 (or mock transfected); vinculin provided a protein loading control (1 representa-
tive experiment of 5 repetitions). (D) Viability of drug-resistant (or parental) A375 and SK-MEL-28 cells, transfect-
ed with miR-338 or mock (as shown in B; values normalized to respective mock-transfected cells) (n = 3).
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Figure 3. NRP1 controls the therapeutic 
response to targeted therapy in MET 
oncogene–addicted cancer cells. (A) NRP1 
expression was assessed by immunoblot-
ting in GLT16 (gastric cancer), EBC1 (lung 
cancer), and H1993 (lung cancer) Met- 
addicted cells; β-actin provided a protein 
loading control (1 representative experi-
ment of 2 repetitions). (B) The viability of 
the Met-addicted cells described in A was 
assessed by Cell Titer Glo Viability Assay 
upon NRP1 knockdown by RNA interference 
(n = 3). (C–H) The viability of GTL16 (C and 
D), EBC1 (E–G), and H1993 cells (H), either 
NRP1-depleted or mock-transfected (same 
cells as in B), was assessed in the presence 
of increasing concentrations of the Met 
inhibitors indicated below the graphs: 
JnJ-38877605 (JNJ-605), PHA-665752, or 
crizotinib (n > 5). IC50 values were calculated 
by Graphpad. (I and J) The growth of NRP1- 
depleted or mock-transfected GTL16 (I) and 
EBC1 (J) (same cells as in previous panels) 
was assessed by staining with crystal violet 
and reading Abs 595 nm after 2 weeks in 
culture in the presence of the indicated 
concentrations of the Met inhibitor JNJ-605 
and normalized to untreated control cells 
condition (n = 3). In C–J, the statistical anal-
ysis was done by 2-way ANOVA with Bonfer-
roni’s correction, comparing the behavior of 
NRP1-silenced and control cells.
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a genetic analysis of explanted tumors (Supplemental Figure 4, 
A and B), we found that NRP1hi cells had acquired striking drug 
refractoriness and selective growth advantage, overwhelming the 
mock cell population and enabling tumor development even in 
presence of targeted therapy (Supplemental Figure 4, B–D).
From a mechanistic perspective, we demonstrated that NRP1 
overexpression in MET-addicted carcinoma cells upregulated 
endogenous EGFR levels (Figure 5A and Supplemental Figure 
4E). Interestingly, as in melanoma, a strong correlation between 
NRP1 and EGFR mRNA levels was observed in data sets derived 
from human lung (TCGA), breast (Metabric), and colorectal 
(TCGA) cancer samples (Spearman’s correlation coefficients: 
0.470, 0.376, and 0.252, respectively; P < 0.00001 for all). Nota-
bly, NRP1 upregulation in MET-addicted cells correlated with 
increased EGFR tyrosine phosphorylation and persistence of acti-
vated AKT in MET inhibitor–treated cells (Figure 5B), consistent 
with the notion that an alternative signaling pathway sustains cell 
viability and growth. The functional relevance of EGFR signaling 
in NRP1-induced resistance to MET-targeted therapies was finally 
validated by finding reduced cell viability upon combined treat-
ment with the MET inhibitor in association with EGFR-specific 
inhibitors erlotinib or cetuximab (Figure 5C).
NRP1-dependent upregulation of IGF1R kinase mediates acquired 
resistance to targeted therapy in HER2-addicted breast cancer cells. 
Approximately 20% of human breast cancers are characterized 
by HER2 oncogene amplification and constitutive activation, fea-
turing an addiction that is usually therapeutically targeted with 
HER2 inhibitors. In advanced disease, however, resistance to 
HER2-targeted drugs almost invariably ensues (26). Intriguingly, 
by analyzing RNA-Seq data from a panel of matched breast cancer 
Figure 4. NRP1 expression confers refrac-
toriness to targeted therapy and selective 
growth advantage in vivo to Met-addicted 
cells. (A and B) The viability of EBC1 (A) or 
GTL16 (B) Met-addicted cells, either NRP1 
overexpressing or mock transfected, was 
assessed in the presence of increasing con-
centrations of the indicated Met inhibitors  
(n > 6). IC50 values were calculated by 
Graphpad. (C) NOD-SCID mice were injected 
subcutaneously with a heterogeneous mix of 
EBC1 cells, half control and half overexpress-
ing NRP1 (n = 5, per experimental condition). 
In 2 complementary settings, one of the 
cell populations was previously marked by 
fluorescent Turbo-RFP, featuring a mock-
RFP–labeled mix and a NRP1-RFP–labeled 
mix, which allowed us to follow the growth 
of intermingled fluorescent cells expressing 
different NRP1 levels by in vivo imaging 
with the IVIS Spectrum CT system (y axis). 
As expected, mouse treatment with the 
Met-inhibitor JNJ-605 (2.5 mg/kg by daily oral 
gavage) impaired the growth of control cells 
(revealed by fluorescent signal in mock-RFP 
mix tumors in this bar graph, and by gene 
marker–specific qPCR in Supplemental Figure 
4, A and B). However, NRP1-overexpressing 
cells (revealed by fluorescence in NRP1-RFP 
mix tumors in this bar graph, and by gene 
marker–specific qPCR in Supplemental Fig-
ure 4B) were relatively refractory to targeted 
therapy. Indeed, due to overgrowth of NRP1hi 
cells, all tumors developed irrespective of 
targeted therapy (see Supplemental Figure 4, 
C and D). In all panels, the statistical analysis 
was done by 2-way ANOVA with Bonferroni’s 
correction, comparing the behavior of NRP1hi 
and mock-transfected control cells;  
***P < 0.0001.
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samples (and cell lines) before and after targeted therapy (27), in 
most cases we found NRP1 upregulation in response to treatment 
with the HER2 inhibitor trastuzumab (Supplemental Figure 5, A 
and B). We also observed NRP1 upregulation in HER2-addict-
ed BT474 breast cancer cells treated with the targeted inhibitor 
lapatinib (Supplemental Figure 5C), suggesting an adaptive drug- 
induced response. Notably, the analysis of RNA-Seq data derived 
from BT474 cells subjected to HER2 silencing clearly indicated 
increased NRP1 levels (Supplemental Figure 5D), suggesting that 
NRP1 expression in these cells is basally constrained by constitu-
tively active HER2 signaling.
We therefore set out to test the role of NRP1 in the respon-
siveness of HER2-addicted cancer cells to targeted therapies, by 
treating BT474 and SKBR3 with escalating doses of lapatinib until 
the onset of drug resistance. Indeed, we found strong upregulation 
of NRP1 in drug-resistant cells, both at mRNA and protein levels 
(Figure 6A and Supplemental Figure 5E). Moreover, gene silencing 
confirmed the functional requirement of NRP1 in mediating resis-
tance to targeted therapy (Figure 6B), whereas its depletion had no 
significant impact on the viability of parental HER2-addicted cells. 
Using a complementary approach, we found that NRP1 overex-
pression was sufficient to confer resistance to lapatinib treatment 
in the same cells (Supplemental Figure 5F). These data confirmed 
the concept that NRP1 upregulation is a mechanism that sustains 
cancer viability and proliferation in a range of cancer cells. We also 
asked whether miR-338, which we found to regulate NRP1 expres-
sion in melanoma cells, could play a 
similar role in breast cancer. Actually, 
the upstream controller SOX10 is a 
lineage-specific transcription factor 
that is not expressed in carcinomas. 
Consistently, we found that miR-338 
was not downregulated in SKBR3 and 
BT474 carcinoma cells upon the onset 
of resistance to HER2 inhibitors (not 
shown). Thus, NRP1 upregulation 
associated with resistance to targeted 
therapy can be due to different mecha-
nisms in different tumor types.
Notably, lapatinib is a dual-kinase 
inhibitor that, in addition to HER2, tar-
gets EGFR. Thus, we were not expect-
ing to find activated EGFR as a resis-
tance mechanism in this experimental 
model. Indeed, we did not observe 
HER2 or EGFR phosphorylation in 
drug-resistant cells, whereas in an 
unbiased phosphoprotein screening we 
found a marked upregulation of IGF1R 
expression and activity (Supplemental 
Figure 6A), which was then validated 
by Western blotting (Figure 6C). Using 
the approach followed for investigat-
ing BRAF- and MET-addicted cells, we 
demonstrated the requirement of NRP1 
to induce IGF1R in drug-resistant cells 
(Figure 6D). Moreover, whereas paren-
tal breast cancer cells were not dependent on IGF1R, their drug- 
resistant derivatives relied on IGF1R activity to sustain refractori-
ness to HER2-targeted therapy (Supplemental Figure 6B). Intrigu-
ingly, we verified that IGF1R was not induced in melanoma cells 
upon the onset of BRAF-inhibitor resistance (Supplemental Figure 
6C), nor was it implicated in the loss of drug efficacy (Supplemental 
Figure 6D), indicating that NRP1 can sustain diverse mechanisms 
of refractoriness to therapy mediated by distinctive RTKs.
NRP1 drives EGFR and IGF1R upregulation via JNK kinase activ-
ity and SOX2/JUN transcription factors. We set out to investigate 
the molecular mechanisms by which the NRP1-induced signaling 
cascade elicits EGFR and IGF1R transcriptional upregulation in 
drug-refractory cells. Intriguingly, it was reported previously that 
NRP1, via its intracellular adapter GIPC, negatively regulates the 
CDK-inhibitor p27-Kip1 (10, 28), which in turn is known to cur-
tail EGFR levels by inhibiting the upstream regulator JNK (29). 
Indeed, JNK kinase is one of the intracellular signal transducers 
activated by NRP1 (30). We found p27 downregulation at mRNA 
and protein levels (Figure 7, A and B), and increased phosphory-
lated (active) JNK in drug-resistant melanoma and breast cancer 
cells (compared with parental), as well as in NRP1-overexpressing 
EBC1 cells (Figure 7B). Conversely, NRP1 downregulation caused 
by miR-338 reexpression in drug-resistant melanoma cells trig-
gered a cascade leading to p27 increase and pJNK suppression 
(Supplemental Figure 7A). In keeping with these data, silenc-
ing endogenous NRP1 levels in EBC1 carcinoma cells overtly 
Figure 5. NRP1 upregulates EGFR in carcinoma cells resistant to Met-targeted inhibitors. (A) NRP1 and 
EGFR expression was analyzed by immunoblotting in the indicated Met-addicted cells, either control or 
transduced to overexpress NRP1; vinculin provided a protein loading control (1 representative experiment 
of 5 repetitions). (B) EBC1 cells overexpressing NRP1 (or mock controls) were analyzed by Western blotting 
to reveal the expression and the phosphorylation levels of Met and EGFR tyrosine kinases, as well as their 
intracellular effector AKT (1 representative experiment of 4 repetitions; duplicate samples were run on 
parallel gels). (C) The viability of EBC1 cells overexpressing NRP1 (or mock controls) was assessed in the 
presence of the Met-inhibitor JNJ-605 (15 nM), either alone or in combination with the EGFR inhibitors 
cetuximab (1 μg/ml) or erlotinib (1 μM). Statistical significance was calculated by Student’s t test with 
Bonferroni’s correction, comparing each cetuximab- or erlotinib-treated condition versus respective vehi-
cle-treated conditions (n = 6); **P < 0.001.
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Interestingly, we did not observe 
SOX2 upregulation in HER2 inhibi-
tor–resistant breast cancer cells (not 
shown), suggesting the involvement 
of alternative transcriptional factors 
in the upregulation of IGF1R tyro-
sine kinase. Indeed, we found that 
in this system another JNK-activat-
ed factor reported to control IGF1R 
transcription, c-JUN (34, 35), was 
induced in drug-resistant cells in 
a JNK-dependent manner (Figure 
8D). Importantly, knocking down 
JUN prevented the upregulation 
of IGF1R, the RTK responsible for 
drug resistance in breast cancer cells 
(Figure 8E and Supplemental Figure 
7, G and H). Altogether, these data 
suggest a novel intracellular path-
way controlled by NRP1 in cancer 
cells, dependent on its intracellular 
adapter GIPC, and on the negative 
and positive regulators p27 and 
JNK, respectively, and responsible 
for SOX2/JUN-mediated transcrip-
tional upregulation of RTKs (sche-
matic representation in Figure 8F).
Since diverse JNK kinase–
dependent signaling cascades are 
implicated to mediate NRP1-induced 
refractoriness to oncogene-targeted 
drugs in multiple tumor models, we 
asked whether a JNK inhibitor could 
be used to counteract or prevent 
resistance to therapy. Notably, JNK 
inhibition per se did not have a significant impact on cancer cell via-
bility; however, drug-refractory melanoma and breast cancer cells 
were significantly resensitized to oncogene-targeted drugs when 
cotreated with a JNK inhibitor (Supplemental Figure 7I). Moreover, 
the presence of JNK inhibitor prevented the development of drug 
resistance that usually arises in SK-MEL-28 melanoma cells after 5 
weeks of treatment with the BRAF inhibitor PLX-4720 (Figure 8G).
NRP1-interfering molecules extend the efficacy of targeted thera-
py and resensitize drug-resistant cells to oncogene inhibitors. In order 
to validate the potential translational relevance of targeting NRP1 
protein to improve the therapeutic response to oncogene-target-
ed drugs, we assayed combined kinase inhibitor treatments with 
NRP1-interfering molecules. Specifically, we applied the small 
molecule NRP1 inhibitor EG00229, previously found to inter-
act with the extracellular b1b2 domain of NRP1 and to prevent 
the transactivation of the neuropilin-associated tyrosine kinase 
VEGFR2 (36). In addition, we generated NRP1-specific nano-
bodies, which are camelid single-domain antibody fragments 
(37). The generation and characterization of these nanobod-
ies are described in detail in Methods. Of note, nanobody HS45 
(Nb-HS45) recognizes human NRP1 with a high affinity (KD: 4.23 
nM), whereas it does not recognize its orthologue NRP2. Treat-
upregulated p27 and repressed pJNK (Figure 7C). Moreover, the 
mechanistic role of the NRP1-associated adapter protein GIPC in 
this pathway was validated by knockdown experiments in NRP1- 
dependent drug-resistant cells, resulting in increased p27 and 
consequent impairment of EGFR or IGF1R upregulation (Sup-
plemental Figure 7B). Notably, p27 reexpression by transfection 
was sufficient to revert NRP1-dependent pJNK induction and 
EGFR upregulation (Figure 7D and Supplemental Figure 7, C and 
D). Importantly, inhibition experiments showed that JNK kinase 
activity is required to mediate this novel NRP1-induced signal-
ing cascade leading to EGFR or IGF1R upregulation in diverse 
drug-refractory cells (Figure 7, E–G and Supplemental Figure 7E).
Hence, we asked about transcription factors regulated by 
JNK and potentially implicated in the upregulation of EGFR and 
IGF1R. One candidate was SOX2, an upstream regulator of EGFR 
expression (31, 32), previously found to be associated with cancer 
cell stemness and resistance to targeted therapy (33). Notably, we 
discovered that SOX2 levels were dramatically increased in BRAF 
inhibitor–resistant melanoma and NRP1-overexpressing carcinoma 
cells, in a JNK kinase–dependent manner (Figure 8A). In fact, SOX2 
silencing reverted NRP1-dependent induction of EGFR in drug- 
resistant cells (Figure 8, B and C and Supplemental Figure 7F).
Figure 6. NRP1 upregulation in HER2-addicted breast carcinoma cells mediates acquired resistance to 
targeted therapy. (A) Immunoblotting analysis of NRP1 expression in the indicated breast cancer cells, either 
parental naive or with acquired resistance to the HER2-inhibitor lapatinib (Lap) (250 nM for BT474 and 120 nM 
for SKBR3); vinculin provided a protein loading control (1 representative experiment of at least 3 repetitions). 
(B) The same cells described in A were subjected to NRP1 knockdown by shRNAs (or treated with plkO empty 
vector); the fraction of cells resistant to lapatinib (same concentrations as indicated above) was defined as 
residual viability in presence of the drug versus untreated conditions (n > 4). (C) Immunoblotting analysis 
of IGF1R expression and tyrosine phosphorylation in lapatinib-resistant BT474 cells; vinculin provided a 
protein loading control (1 representative experiment of 3 repetitions). (D) IGF1R mRNA expression levels were 
measured by qPCR in parental or lapatinib-resistant BT474 cells, either control or upon NRP1 silencing (n = 3). 
Statistical significance was assessed by Student’s t test; ***P < 0.0001.
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molecules could also affect normal non–oncogene-addicted cells. 
Actually, neither viability nor growth of primary HUVECs, immor-
talized normal HEK-293 kidney cells, or 3T3 fibroblasts were 
affected by treatment with high doses of EG00229 or HS45 nano-
bodies (Supplemental Figure 9, A–C). Experiments were aimed at 
revealing potential short- or long-term toxicities. Moreover, we 
assayed combined treatments with oncogene- and NRP1-targeted 
molecules, as was done for cancer cells (Supplemental Figure 9D).
Discussion
A major challenge of precision oncology is dealing with acquired 
resistance to targeted therapies. Understanding the molecular 
mechanisms of resistance is therefore of paramount importance 
to improve treatment efficacy. For instance, melanoma resistance 
to BRAF inhibitors is accounted for by a range of different mech-
anisms. In around one-third of cases, the mechanism is epigene-
tic regulation of gene expression, which often leads to increased 
receptor tyrosine kinase signaling (38, 39). We and others have 
previously shown that BRAF-addicted melanoma cells, upon 
treatment with targeted inhibitors, undergo adaptive gene expres-
sion reprogramming and develop secondary drug resistance asso-
ciated with the upregulation of EGFR tyrosine kinase (17, 40). 
Here we show that de novo NRP1 expression in melanoma cells is 
a pivotal driver of this process. The same drug-resistance mecha-
nism was confirmed in oncogene-addicted carcinoma cells upon 
ment with either of these NRP1-interfering molecules enhanced 
the activity of MET kinase inhibitors and promoted cancer cell 
viability loss at significantly lower drug concentrations, with up to 
8-fold–reduced IC50 (Figure 9A and Supplemental Figure 8, A–C). 
Notably, upon MET signaling blockade, ligand-dependent EGFR 
activation could sustain intracellular AKT and MAPK signaling 
in these cells, whereas NRP1-blocking nanobodies negated this 
effect (Supplemental Figure 8D), indicating inability of the EGFR 
pathway to mediate survival after targeted therapy. Similarly, we 
found that combined treatment with EG00229 restored the ther-
apeutic response to lapatinib in drug-resistant breast cancer cells 
(Figure 9B). We finally tackled the NRP1-dependent onset of 
resistance to BRAF inhibitors in SOX10-deficient melanoma cells, 
by applying EG00229 or anti-NRP1 nanobodies, and found that 
this could prevent EGFR upregulation (Figure 9C) and acquired 
refractoriness to targeted therapy (Figure 9D). Furthermore, the 
functional inhibition of NRP1 in PLX-4720–resistant melanoma 
cells resulted in a significant recovery of drug sensitivity and long-
term therapeutic response (Figure 9E). Notably, EG00229 syner-
gized with cetuximab to achieve resensitization of melanoma cells 
to targeted therapy (Figure 9F).
Thus, NRP1 functional interference strongly enhanced the 
efficacy of oncogene-targeted therapies and prevented the onset 
of drug resistance. In consideration of the potential therapeutic 
relevance of this approach, we wondered whether NRP1-targeted 
Figure 7. p27 decrease and JNK activation mediate NRP1-driven EGFR and IGF1R upregulation. (A) p27 mRNA levels were measured by qPCR (n > 3) in the 
indicated cancer cell lines: A375 and SK-MEL-28 (parental or resistant to PLX-4720), BT474 (parental or resistant to lapatinib), and EBC1 (NRP1 overexpress-
ing or mock transfected). (B) p27-Kip1, activated phospho-JNK, and total JNK protein levels in cancer cells described in A (1 representative experiment of 4 
repetitions; duplicate samples were run on parallel gels). The values at the bottom indicate densitometric measurement of relative p-JNK versus total JNK 
band intensity. (C) NRP1, p27, p-JNK, and total JNK levels in EBC1 cells subjected to NRP1 silencing (1 representative experiment of 3 repetitions; duplicate 
samples were run on parallel gels). (D) p-JNK and EGFR levels in EBC1 cells (shown in B), subjected to p27 overexpression (1 representative experiment of 3 
repetitions; duplicate samples were run on parallel gels). (E) qPCR analysis of EGFR expression in SK-MEL-28 melanoma cells, parental or PLX-4720 resis-
tant, upon treatment with the JNK kinase inhibitor SP600125 (25 μM; JNK-i) or with vehicle alone (n = 5). (F) EGFR expression in EBC1 cells (shown in B), 
either in basal conditions (Veh) or in the presence of 25 μM SP600125 (1 representative experiment of 6 repetitions). (G) IGF1R levels in BT474 cells (shown 
in B), either in basal conditions or in the presence of 25 μM SP600125 (1 representative experiment of 5 repetitions). **P < 0.001, ***P < 0.0001.
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cells due to a SOX10/miR-338 pathway targeting its transcript in 
neural crest–derived cells, this restriction mechanism is blunted 
in response to target therapy, enabling NRP1 upregulation and the 
onset of drug resistance. In carcinoma cells, which do not carry 
the SOX10/miR-338 regulatory axis, the regulation of this miRNA 
doesn’t seem to be associated with drug resistance (not shown); 
in fact, other mechanisms have been implicated in NRP1 upregu-
lation in carcinoma cells (41–43), and could be postulated to elicit 
the adaptive response to targeted therapy. Moreover, we report 
here that NRP1 expression may be unleashed upon inhibition of 
HER2 constitutive activity in breast cancer cells.
NRP1 overexpression, consistent with the idea that NRP1 acts as 
a common trigger to upregulate pathways sustaining cancer cell 
survival and growth under life-threatening conditions. In fact, we 
and others have previously shown that a range of carcinoma cell 
lines are dependent on NRP1 for viability and proliferation, which 
may relate to the ability of NRP1 to stimulate multiple growth 
factor receptors (9, 12). Here we show that cancer cells carrying 
a constitutively activated oncogene are not dependent on NRP1; 
however, NRP1 regains its pivotal growth-promoting role when 
the oncogenic addiction pathway is blocked by targeted inhibi-
tors. Moreover, whereas NRP1 is barely detectable in melanoma 
Figure 8. SOX2 and JUN transcription factors mediate NRP1/JNK-driven upregulation of EGFR and IGF1R, respectively. (A) qPCR analysis of SOX2 expres-
sion in parental and drug-resistant A375 and EBC1 cells (shown in B), either in basal conditions or in the presence of 25 μM SP600125; values normalized to 
untreated controls (n = 5). (B) qPCR analysis of EGFR expression in parental and drug-resistant A375 cells subjected to SOX2 silencing by targeted siRNAs 
(validated in Supplemental Figure 7F) (n = 4). (C) EGFR expression in EBC1 cells (shown in B), subjected to SOX2 silencing (validated in Supplemental 
Figure 7F) (1 representative experiment of 4 repetitions). (D) qPCR analysis of JUN expression in parental and drug-resistant BT474 cells, either in basal 
conditions or in the presence of 25 μM SP600125; values normalized to untreated parental cells (n = 3). (E) IGF1R expression in BT474 cells (same as above), 
subjected to JUN silencing by RNAi (validated in Supplemental Figure 7G) (1 representative experiment of 4 repetitions). (F) Schematic working model of 
the proposed signaling cascade leading to the onset of resistance to oncogene-targeted therapy in different cancer cells. The upstream regulation of NRP1 
levels by miR-338-3p (marked in red) was specifically observed in melanoma cells, whereas in carcinoma cells NRP1 expression might depend on RTK-Ras 
signaling cascade (marked in blue). (G) SK-MEL-28 cell viability was assessed upon treatment with 1 μM PLX-4720, alone or in association with the indicat-
ed concentrations of JNK-i SP600125. While naive cells were initially sensitive to PLX-4720, after 3–5 weeks in culture they progressively developed drug 
resistance, but this was prevented in the presence of JNK-i (n > 3). In all panels, statistical significance was assessed by Student’s t test with Bonferroni’s 
correction; *P < 0.01, **P < 0.001, ***P < 0.0001.
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TGFβ1 signaling as well as other potentially relevant growth fac-
tor pathways (11, 12). In fact, here we demonstrate that NRP1 is 
critically required to mediate and maintain adaptive EGFR upreg-
ulation in melanoma cells and resistance to BRAF-targeted ther-
apies, both in vitro and in mouse models. Moreover, a combined 
treatment with a NRP1 inhibitor and cetuximab, targeting both 
EGFR expression and signaling, could achieve full resensitization 
to therapy of drug-resistant melanoma cells.
Interestingly, NRP1 has been implicated in the control of 
additional tyrosine kinase receptors besides EGFR, putatively 
accounting for its ability to promote the growth of a wide range 
of cancer cells. In this line, we found that NRP1 is also upregu-
lated in HER2-addicted breast cancer cells subjected to targeted 
therapy. NRP1 is pivotal in this system to induce IGF1R tyrosine 
kinase expression and activity, a mechanism known to mediate 
resistance to HER2-targeted inhibitors (45). Similar to what we 
observed for melanoma, NRP1 upregulation is frequently seen in 
breast cancer samples upon treatment with HER2 inhibitors. Pro-
spective studies will be required to assess if NRP1 upregulation is a 
common trait in HER2-amplified breast cancers developing resis-
We have previously shown that NRP1 promotes ligand- 
induced EGFR receptor clustering at the cell surface (9). How-
ever, here we demonstrate that NRP1 is also an important trig-
ger of EGFR upregulation at a transcriptional level, which fur-
ther empowers its activity in support of cancer cell viability and 
growth. In keeping with these findings, bioinformatic analysis of 
human tumor sample data sets demonstrated a strong direct cor-
relation between NRP1 and EGFR gene expression in melanomas, 
as well as lung, colorectal, and breast carcinomas. We found that 
NRP1-dependent EGFR upregulation is elicited through a novel 
signaling cascade mediated by JNK kinase and the transcription 
factor SOX2. Notably, both NRP1 and SOX2 have been previously 
associated with cancer cell stemness (21, 44); thus, future studies 
may address the question of whether the functional role of NRP1 
in stem cell renewal could be mediated by SOX2 activity. Our data 
unveil a novel function of JNK kinase, eliciting SOX2 and EGFR 
upregulation in cancer cells. Our findings do not exclude that oth-
er factors besides NRP1 could control EGFR levels in cancer. For 
example, TGFβ1 can also induce EGFR expression in melanoma 
cells (17), and intriguingly, NRP1 has been reported to enhance 
Figure 9. Therapeutic efficacy of NRP1-inter-
fering molecules in combination with BRAF-, 
HER2-, or Met-targeted inhibitors. (A) The 
viability of EBC1 Met-addicted cells (n = 5) was 
assessed upon treatment with increasing con-
centrations of the Met inhibitor JNJ-605, either 
alone or in combination with the NRP1-targeted 
molecule EG00229 (12.5 μM) or the nanobody 
HS45 (5 μg/ml). (B) HER2-addicted BT474 
breast cancer cells, either parental naive or 
resistant to the targeted inhibitor lapatinib  
(250 nM), were exposed to lapatinib alone or 
in combination with EG00229 (12.5 μM); the 
fraction of drug-resistant cells was calculated 
based on residual viability versus untreated 
conditions (n = 4). (C) EGFR mRNA levels were 
measured in SOX10-depleted A375 melano-
ma cells (or controls) (n = 4), treated with the 
NRP1-targeted molecule EG00229 (12.5 μM) or 
with vehicle alone. (D) Viability of SOX10- 
depleted A375 melanoma cells (or controls) (n 
> 4) exposed to 0.25 μM PLX-4720, either alone 
or in combination with the small molecule 
EG00229 (12.5 μM) or HS45 nanobody (5 μg/
ml). (E) The growth of A375 melanoma cells, 
parental or PLX-4720 resistant (n = 3), was 
assessed after 2 weeks of culture in the pres-
ence of the BRAF inhibitor PLX-4720, either 
alone or in combination with 12.5 μM EG00229 
(representative images at the bottom). (F) 
Residual viability of BRAF inhibitor–resistant 
A375 melanoma cells subjected to different 
therapeutic associations of PLX-4720 (2 μM) 
with cetuximab (1 μg/ml) and/or EG00229 (12.5 
μM); the statistical analysis compared combi-
natorial treatments with PLX-4720 alone (n = 
5). We applied ANOVA tests with Bonferroni’s 
correction to analyze multiple sample com-
parisons in A, D, F; in the other cases, we used 
Bonferroni-corrected Student’s t tests;  
*P < 0.01, **P < 0.001, ***P < 0.0001.
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(47, 48). These data suggest that therapeutic tools interfering with 
NRP1, applied in combination with oncogene-targeted therapies, 
could be used not only to prevent drug-resistance in cancer cells, 
but also to promote environmental conditions favorable to cancer 
cell clearance. Future studies validating specific NRP1-interfering 
molecules applicable in vivo for this purpose should therefore be 
performed in immunocompetent murine preclinical models.
In sum, our study provides the rationale for targeting NRP1- 
dependent mechanisms responsible for adaptive resistance to the 
blockade of activated oncogenes.
Methods
Human cell lines. HEK-293T kidney cells, A549 and H1993 lung adeno-
carcinoma cell lines, and the A375 melanoma cell line were provided 
by American Type Culture Collection (ATCC). SK-MEL-5, SK-MEL-28, 
and SK-MEL-2 melanoma cells were provided by the National Cancer 
Institute (NCI). The BT474 breast ductal carcinoma cell line was pro-
vided by DMSZ, and SKBR3 breast adenocarcinoma was provided by 
the Interlab Cell Line Connection (ICLC). EBC1 human lung squamous 
cell carcinoma line was purchased from the Health Science Research 
Resources Bank (HSRRB). GTL16 is a clonal cell line established in our 
laboratory and derived from the poorly differentiated gastric carcino-
ma cell line MKN45. Primary HUVECs were cultured in EGM2 medi-
um (Lonza). All tested and authenticated cancer cell lines used in this 
study were cultured in the following media: RPMI for EBC1, GTL16, 
H1993, A549, BT474, SK-MEL-5, SK-MEL-28, and SK-MEL-2 cells; and 
DMEM for HEK-293T, SKBR3, and A375 cells. The media were sup-
plemented with 1% l-glutamine (2 mM), 10% FBS (Sigma), penicillin 
(5,000 U/ml, Faber), and 0.1% streptomycin (5 mg/ml, Squibb) and 
incubated in a humidified incubator with 5% CO2 at 37°C. Cell lines 
were passaged in culture for fewer than 6 months after resuscitation.
Analysis of mRNA expression in tumor samples. We compared SOX10, 
NRP1, and EGFR mRNA levels in 12 matched melanoma samples, each 
derived from the same patient before and while undergoing treatment 
with BRAF inhibitors. Ten of these were described in the study published 
by Kwong and coworkers (49) (data set accession: EGAD00001001306 
at www.ebi.ac.uk), whereas an additional 2 were described in our previ-
ous study (17). We compared NRP1 mRNA levels in 11 matched breast 
cancer samples, each derived from the same patient before and while 
undergoing treatment with HER2 inhibitor (27). Raw data files can be 
found in NCBI’s Gene Expression Omnibus database (GEO GSE60182).
Antibodies and other reagents. Anti–neuropilin-1 antibody used for 
Western blot analysis was purchased from Abcam (ab813121). EGFR 
was detected by antibodies purchased from Santa Cruz Biotechnolo-
gy (clone 1005; sc-03) or Enzo Life Sciences (ALX-804-064-C100). 
EGFR phosphorylation was detected by a phospho-specific antibody 
from Abcam (directed to p-Tyr1068; catalog ab5644). SOX10 antibody 
was purchased by Abcam (ab155279). Anti-IGF1Rβ was purchased 
by Santa Cruz Biotechnology (sc-713). GIPC antibody was provided 
by Santa Cruz Biotechnology (sc-35475). Total and phosphorylated 
MAPK and AKT (pAKT-S473 and pMAPK-Thr202/Tyr204) and pJNK (cat-
alog 4668) were detected with antibodies from Cell Signaling. Other 
antibodies applied in this study were anti-vinculin (V4505, Sigma), 
anti–β-actin (clone I-19, Santa Cruz Biotechnology), and anti–β-tubulin 
(T4026, Sigma). Secondary antibodies were purchased from Promega 
or Jackson Laboratories. Phospho-RTK Array (catalog ARY001B) was 
purchased from R&D Systems. PLX-4720 was purchased from Med-
tance to targeted therapy. In the present work, we demonstrated 
that NRP1-dependent IGF1R upregulation in breast cancer cells 
also requires JNK kinase, whereas c-JUN, a different transcription 
factor instead of SOX2, is implicated downstream. Altogether, 
these findings underscore a broad relevance of NRP1 activity in 
the onset of multiple adaptive mechanisms of cancer cell resis-
tance to therapies targeting oncogene addiction.
From a mechanistic perspective, we found that NRP1-depen-
dent upregulation of both EGFR and IGF1R is elicited through a 
novel signaling cascade conserved in diverse cancer cells, and is 
mediated by JNK kinase, which gets activated upon NRP1-depen-
dent downregulation of the inhibitor p27, consistent with previous 
data (10, 28). This novel pathway seems to rely on the function 
of the adapter protein GIPC/synectin, which is known to interact 
with the NRP1 intracellular domain (46). However, the implicat-
ed mechanisms leading to NRP1-dependent p27 downregula-
tion need to be clarified. Furthermore, although increased NRP1 
protein expression is sufficient to trigger this pathway in cancer 
cells, it is presently unknown whether the mechanism is ligand- 
independent or not. Intriguingly, our data suggest that VEGF sig-
nals are not implicated. Notably, the pivotal role of JNK in this 
pathway was further confirmed by the association of a JNK inhibi-
tor with therapies targeting oncogenic addiction, an approach that 
could effectively prevent the onset of drug refractoriness and part-
ly revert it in stably drug-resistant cells.
Considering the impact of NRP1 signaling on multiple signaling 
pathways bolstering cancer cell viability and growth, this adaptive 
surge of NRP1 in response to therapy is posited to be an important 
mechanism of acquired drug resistance in cancer patients, consis-
tent with what we showed in vitro and in preclinical mouse models. 
Moreover, NRP1 levels strongly affected up front the sensitivity to 
targeted drugs of carcinoma cells addicted to the Met oncogene, 
consistent with the idea that elevated expression of NRP1 in diverse 
tumors is mechanistically associated with poor response to onco-
gene-targeted therapies. In a translational perspective, NRP1- 
interfering molecules with potential clinical application in com-
bined therapeutic regimens could include targeted nanobodies or 
small molecules interacting with the extracellular domain, such 
as those we found capable of preventing or delaying the onset of 
resistance in melanoma cells, or even of reverting established drug 
resistance in experimental models. Interestingly, our data suggest 
that these NRP1-targeting molecules do not cause nonspecific cell 
toxicity in culture. However, in vivo experiments are warranted to 
support further developments in therapeutic perspective. Notably, 
it can be envisaged that HS45 nanobodies act in a different man-
ner compared with classical anti-NRP1 antibodies previously tested 
in cancer therapy, which were selected for interfering with VEGF- 
induced functions. Indeed, NRP1-dependent resistance to target 
therapies doesn’t seem to be associated with VEGF signaling.
Although in the present study we focused on the role of NRP1 
in cancer cells, this molecule is also widely expressed in the micro-
environment (e.g., in endothelial cells of tumor vessels) as well as 
in tumor-associated macrophages (TAMs) and regulatory T lym-
phocytes (Tregs) (12). In these cell types, NRP1 was also reported to 
promote tumor development, and its cell-specific genetic depletion 
in mice led to defective TAM recruitment, reduced tumor vascula-
ture and tumor growth, and increased antitumor immune response 
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duced in HEK-293T packaging cells by cotransfection with the calcium 
phosphate precipitation method. Target cells were then incubated with 
the conditioned media derived from transfected 293T cells, in the pres-
ence of polybrene 8 μg/ml, for 8–12 hours. This method ensured stable 
gene transfer with very high efficiency (over 95% transgene-positive 
cells, as determined by immunostaining) without the need to select 
individual cell clones. In addition, to rule out variability of biological 
responses, at least 3 independent batches for each construct that was 
used to transduce cells were tested. In order to induce NRP1 expres-
sion, lentiviral-mediated gene transfer was applied by transducing 
vectors containing human NRP1 cDNA subcloned into the puromycin- 
selectable NSPI lentiviral transfer plasmid (provided by Gera Neufeld, 
Israel Institute of Technology, Haifa, Israel).
Gene expression knockdown by RNA interference. NRP1 expression 
was silenced in tumor cells by transfecting targeted siRNA sequences 
(with Lipofectamine 2000, Invitrogen) or by transducing cells with 
shRNA-expressing lentiviral constructs (to achieve stable knockdown). 
EGFR expression was silenced by the following siRNA: GCAGUGACU-
UUCUCAGCAA and GCAGUCUUAUCUAACUAUGAU; SOX2 expres-
sion was silenced using a pool of 2 different siRNA: GGUUGACAC-
CGUUGGUAAU and UGCCGAGAAUCCAUGUAUA; VEGFA was 
knocked down by means of 2 different siRNA: AUGUGAAUGCAGAC-
CAAAG and AUGUGAAUGCAGACCAAAG. Two different sequences 
of chemically synthesized siRNA targeting NRP1 were used as a pool: (a) 
GAGAGGUCCUGAAUGUUCC, (b) AACACCUAGUGGAGUGAUA. 
To achieve long-term expression, the NRP1-targeting sequence above 
(a) was inserted in the lentiviral transfer plasmid pCCLsin.PPT.hPGK.
GFP.Wpre in the frame of a sequence driving the transcription of a 
short-hairpin RNA under control of the H1 promoter, as previously 
reported (52). Control shRNA (shC) was generated by introducing 4 
base substitutions in the NRP1 targeting sequence (GATAGGTCAT-
GACTGCCC). We silenced NRP1 expression by means of a puromycin- 
selectable lentiviral construct TRCN0000323055, provided by Sigma- 
Aldrich; plkO vector was used as control. SOX10 expression was sta-
bly knocked down by means of a doxycycline-inducible shRNA con-
struct, provided by Liqin Wang (The Netherlands Cancer Institute 
[NKI], Amsterdam, The Netherlands), or by a second construct (b, 
above) expressing an independent shRNA sequence in a constitutive 
manner (TRCN0000018984, Sigma-Aldrich). cJUN and GIPC were 
silenced by means of 2 different shRNAs purchased from Sigma- 
Aldrich (cJUN: TRCN0000039591-1 and TRCN0000355647-2; 
GIPC: TRCN0000289267-1 and TRCN0000036769-2). Pre-miRNA 
(miRNA precursor) hsa-miR-338-3p, provided by Ambion (catalog 
PM10716), was transfected with Lipofectamine 2000 (Invitrogen).
RNA isolation and real-time PCR. Total RNA from tumor cell lines or 
tissues was isolated with the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. cDNA preparation was done according to 
standard procedures, using M-MLV Reverse Transcriptase (Promega) 
and oligo-dT primers (Promega). Gene expression was measured using 
the following Taqman gene-specific probes from Thermo Fisher Scien-
tific: NRP1 (Hs00826128_m1), EGFR (Hs00193306_m1), and the house-
keepers GAPDH (Hs04420632_g1) and β-actin (Hs99999903_m1). 
The expression of the following genes was assessed by means of SYBR 
Green–specific primer pairs: SOX10 (Bio-Rad, qHsaCED0038654), 
p27 (CTGAGGACACGCATTTGGT, GGGGAACCGTCTGAAACAT), 
IGF1R (TACGTGAAGATCCGCCATTC, TCGAGGACGTAGAAG-
GAGTAAT), SOX2 (TGGGTTCGGTGGTCAAGTC, GCTCTGG-
ChemExpress. JNJ-38877605 (JNJ-605) was from Selleck Chemicals. 
JNK inhibitor SP600125 was provided by Sigma-Aldrich. IGF1R inhib-
itor BMS-754807 was purchased from Sequoia Research Products. 
The above inhibitors were resuspended in DMSO as vehicle.
Nanobody generation. Anti-NRP1 single-domain antibody (also 
known as nanobody [Nb]) HS45 was isolated from an immune Nb 
phage-display library as previously described (37, 50). An alpaca 
(Vicugna pacos) was immunized via an alternating immunization 
schedule: an injection of 100 μg recombinant human NRP1 (R&D 
Systems) was followed by 100 μg recombinant mouse NRP1 protein 
(R&D Systems) 1 week later. This alternating schedule was main-
tained for a total of 6 weeks; the final injection contained both human 
and mouse Nrp1. Both proteins were mixed with Gerbu LQ 3000 adju-
vant before injection. Peripheral blood lymphocyte mRNA was con-
verted into cDNA, from which Nb-coding sequences were amplified 
and ligated onto the pHEN4 phagemid vector (50). Using M13K07 
helper phages, the Nb library was expressed on bacteriophages in 
E. coli, and specific Nb phages were enriched by 3 rounds of biopan-
ning selection on microtiter plates (Nunc) coated with recombinant 
MMR. Individual colonies were screened in ELISA for antigen recog-
nition and sequenced. The Nb gene of clone HS45, which recognizes 
both mouse and human NRP1, was recloned into the vector pHEN6 to 
encode a C-terminal His6 tag for purification purposes. Prior to use 
in cell culture, the Nbs were incubated 1 to 2 times with Pierce High 
Capacity Endotoxin Removal Resin (Thermo Fisher Scientific) until 
the residual endotoxin level was under the detection limit of the Kinet-
ic Chromogenic LAL Assay (Lonza). Equal amounts of the nontarget-
ed Nb BCII10 (50) were applied as negative control (Nb-ctrl).
Establishment of acquired cancer cell resistance to oncogene-targeted 
inhibitors. In order to establish melanoma cells resistant to PLX-4720, 
we treated naive A375 and naive SK-MEL-28 cells with escalating 
concentrations of the drug (starting from 125 nM and progressively 
increasing the concentration up to 2 μM) until they acquired the ability 
to grow in the presence of PLX-4720 at the same rate as parental cells in 
the absence of the drug. Similarly, we treated BT474 and SKBR3 breast 
cancer cells with escalating concentrations of lapatinib (starting from 
15 nM and progressively increasing the concentration up to 250 nM for 
BT474 and up to 120 nM for SKBR3 cells) until they acquired the ability 
to grow at the same rate as parental cells in the absence of the drug.
Transient cell transfection with cDNA and siRNA. cDNA- and 
siRNA-expressing constructs were transiently transfected in mamma-
lian cells with Lipofectamine 2000 (Life Technologies) according to 
the manufacturer’s instructions. For reverse cell transfection exper-
iments, the cells were transfected immediately after detachment. 
Briefly, the cells were detached with trypsin and counted. In the mean-
time, a mix of siRNA or cDNA, Opti-MEM medium, and lipofectamine 
was prepared (according to the manufacturer’s instructions) and incu-
bated at room temperature for 20 minutes. The transfection mix was 
dispensed first in a 96-well multiwell plate, immediately followed by 
the cell suspension (1 × 103–4 × 103 per well, depending on cell line), 
in quadruplicate points. The transfected cells were directly analyzed 
in the wells 72–96 hours after transfection using cell viability assays.
Gene transfer. p27-expressing cDNA constructs were obtained from 
Addgene (plasmids 15192 and 14049). Lentiviral-mediated gene trans-
fer in mammalian cells was accomplished as previously described (51). 
Nonreplicating viral particles containing transfer plasmids (or empty 
vector noncoding plasmids as control) or targeted shRNAs were pro-
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mice (Charles River Laboratories). Tumor volume was periodically 
measured with a digital caliper during 2 of 3 week-long experiments. 
Two-dimensional fluorescence imaging of red fluorescent protein–
labeled (RFP-labeled) tumor cells in vivo was performed with the IVIS 
Lumina II system (Perkin Elmer). Laser image acquisitions (excitation 
570 nm, emission 620 nm) were done twice a week, analyzing previ-
ously shaved, anesthetized mice. Fluorescent signal in regions of inter-
est was quantified as photon total flux, using Living Image software 
4.3.1 (Perkin Elmer). At the end of the experiment, the mice were euth-
anized and tumor masses were lysed for genomic DNA analysis. For 
drug-treatment experiments, the mice were treated orally by gavage 
with PLX-4720 or JNJ-605 inhibitors (or with DMSO vehicle) diluted 
in a solution of 1% (hydroxypropyl)-methylcellulose (MilliporeSigma, 
catalog H7509) and 0.2% Tween80 (MilliporeSigma, catalog P1754).
Genomic DNA analysis. Explanted tumor xenografts were immedi-
ately snap frozen and homogenized with Ultra Turrex T8. The genom-
ic DNA was then extracted with the ReliaPrep Tissue gDNA Miniprep 
extraction system (Promega) and analyzed using the Applied Biosyste-
ms 7900HT Fast Real-Time PCR System with the following primers: 
U6 (CCCTCGTTGACCGAATCAC, CACCGTGGGCTTGTACTC), 
tRPF (GCAGCAAAGCCTTCATCAAC, CTGCTTCGTATGTGGT-
GATTCT), and puromycin resistance cassette (plkO) (GCGCAGCAA-
CAGATGGAA, CAGACCCTTGCCCTGGT).
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TAGTGCTGGGACA), cJUN (Biorad, qHsaCED0018770), VEGFA 
(TCCGGGTTTTATCCCTCTTC, CCTCTTTCTGCTGGTTTCCA), 
and the housekeeper genes GAPDH (GAAGGTGAAGGTCGGAGTC, 
GAAGATGGTGATGGGATTTC) and β-actin (CACTCTTCCAG-
CCTTCCTTC, GTACAGGTCTTTGCGGATGT). Real-time PCR anal-
ysis was performed using the Applied Biosystems 7900HT Fast Real-
Time PCR System. Total miRNAs were isolated with the miRNeasy 
Mini Kit (Qiagen) according to the manufacturer’s instructions. miRNA 
expression was measured using Taqman gene-specific probes for hsa-
miR-338-3p (catalog 002252) and the housekeeper transcript RNU48 
(catalog 001006) (both from Thermo Fisher Scientific).
Cell proliferation analysis. Tumor cells were seeded in multiple 
96-well plates at an initial density of 1.5 × 103–3 × 103 cells per well 
(depending on the cell line), and subsequently grown in complete medi-
um. At every time point, one multiwell dish was fixed with 11% glutaral-
dehyde, stained with crystal violet, and the absorbance was read using a 
standard colorimetric system at 595 nm.
Cell viability assays. Transduced tumor cells were seeded in 
96-well plastic culture plates at an initial density of 1 × 103–2 × 103 cells 
per well (depending on the cell line) in the presence of the indicated 
drugs or vehicle (DMSO). At 72 hours after cell seeding, the medium 
was changed and cell viability was assessed by CellTiter-Glo Lumines-
cent Cell Viability Assay (Promega) according to the manufacturer’s 
instructions. The number of viable cells was directly proportional to 
the luminescence signal recorded.
Western blotting analysis. Total protein extracts were obtained by 
cell lysis in LB-SDS buffer (25% Tris HCl 0.5M pH 6.8, 25% SDS 10%, 
50% ddH2O). Protein concentrations were quantified by BCA Protein 
Assay kit (Thermo Fisher Scientific) and equal amounts of total cellular 
lysates were separated by SDS-PAGE and transferred to nitrocellulose 
membranes, which were blocked by incubation in 10% BSA. The mem-
branes were incubated in the specific primary antibody properly diluted 
and then in the appropriate peroxidase-conjugated secondary antibody 
(Promega). Signal detection was done by ECL (Amersham Bioscienc-
es, GE Healthcare). Band densitometry analysis was done with ImageJ 
software (NIH) and myImageAnalysis (Thermo Fisher Scientific).
Phosphoproteomic array. The phosphorylation of multiple receptor 
tyrosine kinases was detected using the Proteome Profiler Array Kit 
ARY001 (R&D Systems) according to manufacturer’s protocols.
Statistics. Statistical significance was assessed using the 2-tailed 
Student’s t test or 2-way ANOVA test, with Bonferroni’s correction 
applied when appropriate, as indicated in the figure legends. Error 
bars represent the standard deviation. All experiments were repeated 
at least 3 times (biological replicates). Figures show 1 representative 
experiment, reporting the average of the technical replicates. Aster-
isks indicated statistical significance according to this legend: *P < 
0.01; **P < 0.001; ***P < 0.0001.
Mouse experiments and study approval. Mouse handling and exper-
iments followed international guidelines. The study was approved by 
the local ethical commission and by the Italian Ministry of Health. 
Specifically, 5 × 106 A375 or 2 × 106 EBC1 tumor cells (resuspended 
in 200 μl PBS) were injected subcutaneously in NOD/SCID female 
 1. Torti D, Trusolino L. Oncogene addiction as a 
foundational rationale for targeted anti-cancer 
therapy: promises and perils. EMBO Mol Med. 
2011;3(11):623–636.
 2. Arteaga CL, Engelman JA. ERBB receptors: from 
oncogene discovery to basic science to mech-
anism-based cancer therapeutics. Cancer Cell. 
2014;25(3):282–303.
 3. Johnson DB, et al. Acquired BRAF inhibitor 
resistance: A multicenter meta-analysis of the 
spectrum and frequencies, clinical behaviour, 
and phenotypic associations of resistance mech-
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
3 9 9 0 jci.org   Volume 128   Number 9   September 2018
anisms. Eur J Cancer. 2015;51(18):2792–2799.
 4. Camidge DR, Pao W, Sequist LV. Acquired resis-
tance to TKIs in solid tumours: learning from lung 
cancer. Nat Rev Clin Oncol. 2014;11(8):473–481.
 5. Fallahi-Sichani M, et al. Adaptive resistance of 
melanoma cells to RAF inhibition via reversible 
induction of a slowly dividing de-differentiated 
state. Mol Syst Biol. 2017;13(1):905.
 6. Wilson TR, et al. Widespread potential for growth- 
factor-driven resistance to anticancer kinase 
inhibitors. Nature. 2012;487(7408):505–509.
 7. Rizzolio S, Tamagnone L. Multifaceted role 
of neuropilins in cancer. Curr Med Chem. 
2011;18(23):3563–3575.
 8. Guttmann-Raviv N, Kessler O, Shraga-Heled N, 
Lange T, Herzog Y, Neufeld G. The neuropilins 
and their role in tumorigenesis and tumor pro-
gression. Cancer Lett. 2006;231(1):1–11.
 9. Rizzolio S, et al. Neuropilin-1-dependent reg-
ulation of EGF-receptor signaling. Cancer Res. 
2012;72(22):5801–5811.
 10. Li L, et al. Neuropilin-1 is associated with clini-
copathology of gastric cancer and contributes to 
cell proliferation and migration as multifunction-
al co-receptors. J Exp Clin Cancer Res. 2016;35:16.
 11. Rizzolio S, Tamagnone L. Neuropilins as signal-
ing hubs, controlling tyrosine kinases and other 
cell surface receptors. In: Neufeld G, Kessler O, 
eds. The neuropilins: role and function in health 
and disease. New York, NY: Springer International 
Publishing; 2017:23–39.
 12. Prud’homme GJ, Glinka Y. Neuropilins are 
multifunctional coreceptors involved in tumor 
initiation, growth, metastasis and immunity. 
Oncotarget. 2012;3(9):921–939.
 13. Ding H, et al. Expression and regulation of neu-
ropilin-1 in human astrocytomas. Int J Cancer. 
2000;88(4):584–592.
 14. Lichtenberger BM, Tan PK, Niederleithner H, 
Ferrara N, Petzelbauer P, Sibilia M. Autocrine 
VEGF signaling synergizes with EGFR in tumor 
cells to promote epithelial cancer development. 
Cell. 2010;140(2):268–279.
 15. Liu W, Wu T, Dong X, Zeng YA. Neuropilin-1 is 
upregulated by Wnt/β-catenin signaling and 
is important for mammary stem cells. Sci Rep. 
2017;7(1):10941.
 16. Peng Y, Liu YM, Li LC, Wang LL, Wu XL. Micro-
RNA-338 inhibits growth, invasion and metas-
tasis of gastric cancer by targeting NRP1 expres-
sion. PLoS One. 2014;9(4):e94422.
 17. Sun C, et al. Reversible and adaptive resistance to 
BRAF(V600E) inhibition in melanoma. Nature. 
2014;508(7494):118–122.
 18. Barr MP, et al. Vascular endothelial growth factor 
is an autocrine growth factor, signaling through 
neuropilin-1 in non-small cell lung cancer. Mol 
Cancer. 2015;14:45.
 19. Hamerlik P, et al. Autocrine VEGF-VEGFR2- 
Neuropilin-1 signaling promotes glioma stem-
like cell viability and tumor growth. J Exp Med. 
2012;209(3):507–520.
 20. Grun D, Adhikary G, Eckert RL. VEGF-A acts 
via neuropilin-1 to enhance epidermal cancer 
stem cell survival and formation of aggressive 
and highly vascularized tumors. Oncogene. 
2016;35(33):4379–4387.
 21. Beck B, et al. A vascular niche and a VEGF-Nrp1 
loop regulate the initiation and stemness of skin 
tumours. Nature. 2011;478(7369):399–403.
 22. Goel HL, Mercurio AM. VEGF targets the tumour 
cell. Nat Rev Cancer. 2013;13(12):871–882.
 23. Gokey NG, Srinivasan R, Lopez-Anido C, 
Krueger C, Svaren J. Developmental regulation of 
microRNA expression in Schwann cells. Mol Cell 
Biol. 2012;32(2):558–568.
 24. Liu C, Wang Z, Wang Y, Gu W. MiR-338 suppresses 
the growth and metastasis of OSCC cells by target-
ing NRP1. Mol Cell Biochem. 2015;398(1–2):115–122.
 25. Apicella M, et al. Dual MET/EGFR therapy leads 
to complete response and resistance prevention 
in a MET-amplified gastroesophageal xenopa-
tient cohort. Oncogene. 2017;36(9):1200–1210.
 26. Rexer BN, Arteaga CL. Intrinsic and acquired 
resistance to HER2-targeted therapies in HER2 
gene-amplified breast cancer: mechanisms 
and clinical implications. Crit Rev Oncog. 
2012;17(1):1–16.
 27. Merry CR, McMahon S, Thompson CL, Miski-
men KL, Harris LN, Khalil AM. Integrative 
transcriptome-wide analyses reveal critical 
HER2-regulated mRNAs and lincRNAs in 
HER2+ breast cancer. Breast Cancer Res Treat. 
2015;150(2):321–334.
 28. Yoshida A, et al. VEGF-A/NRP1 stimulates 
GIPC1 and Syx complex formation to promote 
RhoA activation and proliferation in skin cancer 
cells. Biol Open. 2015;4(9):1063–1076.
 29. Fang Y, et al. A new tumour suppression mecha-
nism by p27Kip1: EGFR down-regulation medi-
ated by JNK/c-Jun pathway inhibition. Biochem J. 
2014;463(3):383–392.
 30. Wey JS, et al. Overexpression of neuropilin-1 pro-
motes constitutive MAPK signalling and chemo-
resistance in pancreatic cancer cells. Br J Cancer. 
2005;93(2):233–241.
 31. Chou YT, et al. The emerging role of SOX2 in cell 
proliferation and survival and its crosstalk with 
oncogenic signaling in lung cancer. Stem Cells. 
2013;31(12):2607–2619.
 32. Hu Q, et al. The EGF receptor-sox2-EGF receptor 
feedback loop positively regulates the self- 
renewal of neural precursor cells. Stem Cells. 
2010;28(2):279–286.
 33. Wuebben EL, Rizzino A. The dark side of SOX2: 
cancer - a comprehensive overview. Oncotarget. 
2017;8(27):44917–44943.
 34. Scheidegger KJ, Du J, Delafontaine P. Distinct 
and common pathways in the regulation of  
insulin-like growth factor-1 receptor gene expres-
sion by angiotensin II and basic fibroblast growth 
factor. J Biol Chem. 1999;274(6):3522–3530.
 35. Christopoulos PF, Msaouel P, Koutsilieris M. The 
role of the insulin-like growth factor-1 system in 
breast cancer. Mol Cancer. 2015;14:43.
 36. Jarvis A, et al. Small molecule inhibitors of 
the neuropilin-1 vascular endothelial growth 
factor A (VEGF-A) interaction. J Med Chem. 
2010;53(5):2215–2226.
 37. Schoonooghe S, et al. Novel applications of nano-
bodies for in vivo bio-imaging of inflamed tissues 
in inflammatory diseases and cancer. Immuno-
biology. 2012;217(12):1266–1272.
 38. Van Allen EM, et al. The genetic landscape of 
clinical resistance to RAF inhibition in metastatic 
melanoma. Cancer Discov. 2014;4(1):94–109.
 39. Manzano JL, et al. Resistant mechanisms to 
BRAF inhibitors in melanoma. Ann Transl Med. 
2016;4(12):237.
 40. Wang J, et al. Epigenetic changes of EGFR have 
an important role in BRAF inhibitor-resistant 
cutaneous melanomas. J Invest Dermatol. 
2015;135(2):532–541.
 41. Akagi M, et al. Induction of neuropilin-1 and 
vascular endothelial growth factor by epidermal 
growth factor in human gastric cancer cells. Br J 
Cancer. 2003;88(5):796–802.
 42. Parikh AA, et al. Neuropilin-1 in human colon 
cancer: expression, regulation, and role 
in induction of angiogenesis. Am J Pathol. 
2004;164(6):2139–2151.
 43. Pang HB, et al. An endocytosis pathway initiated 
through neuropilin-1 and regulated by nutrient 
availability. Nat Commun. 2014;5:4904.
 44. Boumahdi S, et al. SOX2 controls tumour initiation 
and cancer stem-cell functions in squamous-cell 
carcinoma. Nature. 2014;511(7508):246–250.
 45. McDermott MSJ, et al. Dual inhibition of IGF1R 
and ER enhances response to trastuzumab in 
HER2 positive breast cancer cells. Int J Oncol. 
2017;50(6):2221–2228.
 46. Cai H, Reed RR. Cloning and characterization of 
neuropilin-1-interacting protein: a PSD-95/Dlg/
ZO-1 domain-containing protein that interacts 
with the cytoplasmic domain of neuropilin-1.  
J Neurosci. 1999;19(15):6519–6527.
 47. Casazza A, et al. Impeding macrophage entry into 
hypoxic tumor areas by Sema3A/Nrp1 signaling 
blockade inhibits angiogenesis and restores antitu-
mor immunity. Cancer Cell. 2013;24(6):695–709.
 48. Overacre-Delgoffe AE, et al. Interferon-γ drives 
Treg fragility to promote anti-tumor immunity. 
Cell. 2017;169(6):1130–1141.e11.
 49. Kwong LN, et al. Co-clinical assessment iden-
tifies patterns of BRAF inhibitor resistance in 
melanoma. J Clin Invest. 2015;125(4):1459–1470.
 50. Conrath KE, et al. Beta-lactamase inhibitors 
derived from single-domain antibody fragments 
elicited in the camelidae. Antimicrob Agents 
Chemother. 2001;45(10):2807–2812.
 51. Follenzi A, Naldini L. HIV-based vectors. Prepara-
tion and use. Methods Mol Med. 2002;69:259–274.
 52. Corso S, Migliore C, Ghiso E, De Rosa G, Como-
glio PM, Giordano S. Silencing the MET onco-
gene leads to regression of experimental tumors 
and metastases. Oncogene. 2008;27(5):684–693.
